Welcome to our dedicated page for Infusystem Hld SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The InfuSystem Holdings, Inc. (NYSE American: INFU) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a national health care service provider that facilitates outpatient care for durable medical equipment manufacturers and health care providers, InfuSystem uses these filings to report financial results, corporate events and other information relevant to investors.
Among the most frequently referenced documents are current reports on Form 8-K. Recent 8-K filings include press releases reporting quarterly financial results, such as the second and third quarter 2025 earnings releases furnished on August 5, 2025 and November 4, 2025. These filings summarize net revenues, segment performance for the Patient Services and Device Solutions platforms, gross margin, cash flow and Adjusted EBITDA, and often discuss factors like revenue mix and information technology projects.
Other 8-K filings furnish Regulation FD disclosures, including investor presentations and announcements of upcoming earnings release dates and conference calls. For example, filings dated July 29, 2025 and October 28, 2025 describe when InfuSystem will issue financial results and how investors can access related conference calls and webcasts. Additional 8-Ks report participation in investor conferences and provide investor presentation materials as exhibits.
InfuSystem has also used Form 8-K to disclose leadership changes and regulatory developments. A filing dated April 1, 2025 describes a CEO transition and reaffirms financial guidance, while a filing dated December 10, 2025 reports that the Centers for Medicare and Medicaid Services added two electronic infusion pumps used in the company’s Pain Management services business to the list of qualifying products for separate payment under the NOPAIN Act.
On Stock Titan, InfuSystem’s SEC filings are supplemented with AI-powered summaries designed to highlight the key points in lengthy documents, such as annual reports on Form 10-K, quarterly reports on Form 10-Q and detailed 8-K exhibits. These tools can help users quickly identify disclosures related to segment performance, capital expenditures on medical devices, information technology upgrade projects, stock repurchase activity, guidance ranges and other topics discussed by the company in its filings.
Investors can use this page to follow InfuSystem’s formal communications with regulators, track how management describes the performance of the Patient Services and Device Solutions platforms, and review historical filings for context on the company’s operations and strategic direction.
InfuSystem Holdings, Inc. has changed its independent auditor for the fiscal year ending December 31, 2026. After a competitive selection process, the board’s Audit Committee dismissed Deloitte & Touche LLP and appointed Grant Thornton LLP to audit the 2026 consolidated financial statements, quarterly reviews, and internal control over financial reporting.
The company states that Deloitte’s audit reports for 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications. It also reports no disagreements or reportable events with Deloitte over those years and through March 13, 2026, and says it did not previously consult Grant Thornton on accounting or audit matters. A confirming letter from Deloitte is filed as an exhibit.
InfuSystem Holdings, Inc. reported that President and Chief Executive Officer Carrie Lachance and Chief Financial Officer Barry Steele will participate in the 38th Annual ROTH Conference on March 23, 2026, at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Management plans to host in-person one-on-one meetings with investors throughout the day, arranged through ROTH Capital conference representatives or the event registration site. The company describes itself as a leading national health care service provider with two main platforms, Patient Services and Device Solutions, supporting outpatient care involving complex durable medical equipment.
InfuSystem Holdings executive Barry G. Steele, Executive VP and CFO, bought 2,064 shares of common stock in open-market purchases at a weighted average price of $9.16 per share. A footnote notes the total holdings also reflect 1,359 shares recently acquired through the company’s Employee Stock Purchase Plan.
InfuSystem Holdings furnished an investor presentation highlighting another year of record results and its long-term growth strategy. Net revenues reached $143.4 million in 2025, up from $134.9 million in 2024, marking seven consecutive years of record revenue. 2025 Adjusted EBITDA increased to $31.5 million, with Adjusted EBITDA margin improving to 21.9% and overall gross margin rising to 56.0%.
The presentation shows a balanced model between Patient Services and Device Solutions, with 2025 revenues of $86.5 million and $56.9 million, respectively. As of December 31, 2025, equity was $57.3 million, total long-term debt $19.6 million, net leverage 0.52x, and total available liquidity $58.2 million. Cash provided by operations over the trailing twelve months was $24.4 million. The company also discussed a renewed $20 million stock repurchase program, under which it had bought back $11 million of shares by year-end 2025.
InfuSystem Holdings, Inc. provides outpatient durable medical equipment services to hospitals, oncology practices, surgery centers and other alternate site providers through two platforms: Patient Services and Device Solutions. Patient Services focuses on clinic‑to‑home oncology and other therapies, while Device Solutions sells, rents and services infusion and wound-care equipment.
The Oncology Business is the lead service in Patient Services and generated about 87% of that segment’s 2025 net revenue, with roughly 43% from colorectal cancer treatments and 44% from non‑colorectal disease states. As of December 31, 2025, the rental fleet had a historical cost of $109.1 million and the company employed 473 people.
InfuSystem highlights competitive advantages from nearly 840 third‑party payer networks, a large pump fleet and seven U.S. and Canadian locations, but warns of extensive risks, including reimbursement changes, dependence on a major pump supplier, regulatory compliance, government shutdowns, cybersecurity threats, tax and macroeconomic uncertainty, and potential limits on using $5.8 million of U.S. federal net operating loss carryforwards.
InfuSystem Holdings, Inc. reported another year of record results for 2025, with full-year net revenue of $143.4 million, up 6% from 2024. Net income rose sharply to $6.6 million, an increase of 183%, while adjusted EBITDA grew 24% to $31.5 million, reflecting stronger profitability.
Fourth-quarter net revenue was $36.2 million, up 7%, and diluted EPS reached $0.10, up 150%. Gross margin improved to 56.0% for the year, and operating cash flow increased 19% to $24.4 million. Net debt declined to $16.4 million as of December 31, 2025, supported by higher cash flow and lower capital spending.
Management highlighted strong growth in Wound Care, with fourth-quarter revenue up over 160%, and continued share repurchases. For 2026, the company restructured its largest biomedical services contract, reducing annual revenue by $7.1 million, or 5.5%, but still expects pro-forma net revenue growth of 6–8% and adjusted EBITDA margins in the mid to low 20% range.
Minerva Advisors LLC and related entities report owning 1,078,731 shares of InfuSystem Holdings common stock, representing 5.3% of the company’s outstanding shares. The ownership is reported on a Schedule 13G/A as of 12/31/2025 and is based on 20,336,183 shares outstanding as of October 31, 2025.
The stake is held across Minerva Advisors LLC, Minerva Group, LP, Minerva GP, LP, Minerva GP, Inc., and David P. Cohen, with 764,517 shares held by Minerva Group, LP. The filers certify the securities are not held for the purpose of changing or influencing control, other than activities solely in connection with a nomination under Rule 14a-11.
InfuSystem Holdings, Inc. filed a current report announcing the timing of its upcoming financial disclosure. The company plans to release preliminary fourth quarter and full-year 2025 results on February 24, 2026 before the market opens.
InfuSystem will host an investor conference call on the same day at 9:00 a.m. Eastern Time to discuss these results, with both live webcast access and a telephone replay available through early March. The filing clarifies that the related press release is furnished under Regulation FD and is not deemed filed for liability purposes.
InfuSystem Holdings, Inc. reported that the Centers for Medicare and Medicaid Services (CMS) has added two of the electronic infusion pumps it uses in its Pain Management services business to the list of qualifying products for separate payment under the Non-Opiods Prevent Addiction in the Nation (NOPAIN) Act. This means those specific non-opioid pain management pumps can be reimbursed separately by CMS, rather than being bundled into broader procedure payments.
The update highlights growing recognition of non-opioid pain management options within federal reimbursement programs, which may help support adoption of InfuSystem’s CMS-qualifying pumps within its Pain Management services line.
InfuSystem Holdings, Inc. furnished an Investor Presentation dated November 13, 2025 under Item 7.01 (Regulation FD). The presentation is attached as Exhibit 99.1.
The materials are expressly furnished, not filed, and therefore are not subject to Section 18 liabilities and are not incorporated by reference into other Securities Act or Exchange Act filings.